Foundation Medicine, a pioneer in molecular profiling for cancer, announced an expanded collaboration with Bristol Myers Squibb to develop Foundation Medicine’s tissue-based test, FoundationOne CDx, as a companion diagnostic (CDx) for Bristol Myers Squibb’s investigational tyrosine kinase inhibitor, repotrectinib.
Repotrectinib is an orally administered TKI (tyrosine kinase inhibitor) being evaluated in an ongoing registrational Phase 1/2 trial called TRIDENT-1 for patients with TKI-naive or TKI-pretreated ROS1+ advanced non-small cell lung cancer (NSCLC) and NTRK+ advanced solid tumors. If the companion diagnostic is approved for these indications, and separately, the therapy is approved, oncologists would be able to use FoundationOne CDx to help identify appropriate patients for treatment with repotrectinib.
Foundation Medicine’s portfolio of FDA-approved comprehensive genomic profiling tests offer physicians blood and tissue-based testing options for detecting genomic alterations that help guide personalized treatment decisions.
“We’re proud to broaden our collaboration with Bristol Myers Squibb as they work to bring this exciting investigational therapy to patients living with ROS1 positive non-small cell lung cancer and NTRK positive solid tumors,” says Jason Adams, VP of Biopharma Enterprise Partnerships, Foundation Medicine. “This new collaboration builds on our ongoing research-driven partnership and furthers our shared commitment to deliver more treatment options to patients who need them.”
